Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and transplantation procedures according to graft type and IPSS

Covariates	BM	PBPC	P	Low + Int-1	Int-2 + High	NA	P
Entire group	132	102		54	104	76
Recipient sex
Male	70	62	NS	32	51	49	NS
Female	62	40		22	53	27
Age at SCT, y
35 or younger	42	16	.004	12	28	18	NS
Older than 35	90	86		42	76	58
Time from diagnosis to SCT
6 months or less	68	55	NS	15	65	31	< .001
More than 6 months	64	47		39	39	45
FAB classification at diagnosis
RA	44	25	.08	40	11	18	< .001
RAEB	40	46		11	44	31
RAEB-t	44	31		3	46	26
Unclassified	4	0		0	3	1
Last disease evaluation
RA	41	19	NS	34	9	17	< .001
RAEB	40	37		13	38	26
RAEB-t	51	46		7	59	31
Disease stage at SCT
Complete remission	42	28	NS	2	40	28	< .001
Untreated	57	46		49	36	18
Treated, not in CR	33	28		3	28	30
Marrow blasts, less than 10%	102	70	NS	45	74	53	NS
Marrow blasts, 10% or more	22	24		9	26	11
Cytogenetics
High-risk cytogenetics	24	14	NS	1	33	4	< .001
Other cytogenetics	65	52		51	52	14
Missing	43	36		2	19	58
Donor sex
Male	74	64	NS	37	61	40	NS
Female	58	38		17	43	36
Donor/recipient sex match
Female-male	27	20	NS	10	17	20	NS
Other combinations	105	82		44	87	56
Nucleated cell dose infused/kg
Less than 3 × 10⁸/kg	45	1	< .001	14	24	8	NS
3 × 10⁸/kg or more	44	58		19	42	41
Total body irradiation
No	60	69	< .001	30	51	48	NS
Yes	71	33		24	53	27
T-cell depletion
No	106	75	NS	35	79	67	NS
Yes	26	27		19	25	9
GVHD prophylaxis
CsA alone	7	5	NS	7	3	2	NS
CsA + corticosteroids	0	1		1	0	0
CsA + MTX	62	38		40	22	38
CsA + MTX + corticosteroids	9	6		10	4	1
With anti–T-cell serotherapy	1	3		3	1	0
Other	2	0		0	1	1
Missing	25	21		18	4	24

Covariates	BM	PBPC	P	Low + Int-1	Int-2 + High	NA	P
Entire group	132	102		54	104	76
Recipient sex
Male	70	62	NS	32	51	49	NS
Female	62	40		22	53	27
Age at SCT, y
35 or younger	42	16	.004	12	28	18	NS
Older than 35	90	86		42	76	58
Time from diagnosis to SCT
6 months or less	68	55	NS	15	65	31	< .001
More than 6 months	64	47		39	39	45
FAB classification at diagnosis
RA	44	25	.08	40	11	18	< .001
RAEB	40	46		11	44	31
RAEB-t	44	31		3	46	26
Unclassified	4	0		0	3	1
Last disease evaluation
RA	41	19	NS	34	9	17	< .001
RAEB	40	37		13	38	26
RAEB-t	51	46		7	59	31
Disease stage at SCT
Complete remission	42	28	NS	2	40	28	< .001
Untreated	57	46		49	36	18
Treated, not in CR	33	28		3	28	30
Marrow blasts, less than 10%	102	70	NS	45	74	53	NS
Marrow blasts, 10% or more	22	24		9	26	11
Cytogenetics
High-risk cytogenetics	24	14	NS	1	33	4	< .001
Other cytogenetics	65	52		51	52	14
Missing	43	36		2	19	58
Donor sex
Male	74	64	NS	37	61	40	NS
Female	58	38		17	43	36
Donor/recipient sex match
Female-male	27	20	NS	10	17	20	NS
Other combinations	105	82		44	87	56
Nucleated cell dose infused/kg
Less than 3 × 10⁸/kg	45	1	< .001	14	24	8	NS
3 × 10⁸/kg or more	44	58		19	42	41
Total body irradiation
No	60	69	< .001	30	51	48	NS
Yes	71	33		24	53	27
T-cell depletion
No	106	75	NS	35	79	67	NS
Yes	26	27		19	25	9
GVHD prophylaxis
CsA alone	7	5	NS	7	3	2	NS
CsA + corticosteroids	0	1		1	0	0
CsA + MTX	62	38		40	22	38
CsA + MTX + corticosteroids	9	6		10	4	1
With anti–T-cell serotherapy	1	3		3	1	0
Other	2	0		0	1	1
Missing	25	21		18	4	24

CsA indicates cyclosporin A; MTX, methotrexate.

P values for Low + Int-1 vs Int-2 + High IPSS.